Bryan Smith Net Worth

The estimated Net Worth of Bryan E. Smith is at least $2.34 Million dollars as of 19 February 2020. Mr. Smith owns over 50,000 units of Urovant Sciences Ltd stock worth over $1,081,000 and over the last 6 years he sold UROV stock worth over $0. In addition, he makes $1,263,660 as General Counsel - USI at Urovant Sciences Ltd.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Smith UROV stock SEC Form 4 insiders trading

Bryan has made over 1 trades of the Urovant Sciences Ltd stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 50,000 units of UROV stock worth $344,000 on 19 February 2020.

The largest trade he's ever made was exercising 50,000 units of Urovant Sciences Ltd stock on 19 February 2020 worth over $344,000. On average, Bryan trades about 7,143 units every 0 days since 2018. As of 19 February 2020 he still owns at least 100,000 units of Urovant Sciences Ltd stock.

You can see the complete history of Mr. Smith stock trades at the bottom of the page.

Bryan Smith biography

Bryan E. Smith J.D. is the General Counsel of USI. From August 2011 to April 2018, Mr. Smith was an Associate Vice President and Senior Counsel at Allergan. At Allergan, he was Chief Counsel to the Allergan Medical Division and was the lead lawyer responsible for the Urology, Neurology and Dermatology divisions. In his capacity as Senior Counsel, he was the legal advisor to Allergan’s executive management, marketing and business teams and provided counsel regarding promotional materials, regulatory requirements for investigational and approved products, regulatory submissions, product labeling, clinical trials and drug safety management. From 2008 to 2011, Mr. Smith was an attorney in the litigation department at the law firm of Gibson, Dunn & Crutcher LLP, and from 2006 to 2008, an attorney at the law firm of Morrison & Foerster LLP. From 2005 to 2006, Mr. Smith was a judicial law clerk to the Honorable Cormac J. Carney of the United States District Court for the Central District of California. He earned a B.A. in Political Science from Brigham Young University and a J.D. from the University of Southern California Law School.

What is the salary of Bryan Smith?

As the General Counsel - USI of Urovant Sciences Ltd, the total compensation of Bryan Smith at Urovant Sciences Ltd is $1,263,660. There are 1 executives at Urovant Sciences Ltd getting paid more, with Cornelia Haag-Molkenteller having the highest compensation of $1,703,470.

How old is Bryan Smith?

Bryan Smith is 40, he's been the General Counsel - USI of Urovant Sciences Ltd since 2018. There are 7 older and no younger executives at Urovant Sciences Ltd. The oldest executive at Urovant Sciences Ltd is Myrtle Potter, 61, who is the Chairman of the Board.

What's Bryan Smith's mailing address?

Bryan's mailing address filed with the SEC is C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE, CA, 92617.

Insiders trading at Urovant Sciences Ltd

Over the last 6 years, insiders at Urovant Sciences Ltd have traded over $0 worth of Urovant Sciences Ltd stock and bought 22,782,569 units worth $411,146,115 . The most active insiders traders include Sciences Ltd. Roivant, Global Investors Lp Viking ... und Andrew Lo. On average, Urovant Sciences Ltd executives and independent directors trade stock every 6 days with the average trade being worth of $6,293,420. The most recent stock trade was executed by Chemical Co., Ltd.Sumitomo ... on 19 February 2020, trading 103,250 units of UROV stock currently worth $1,350,510.

What does Urovant Sciences Ltd do?

Complete history of Mr. Smith stock trades at Urovant Sciences Ltd

Urovant Sciences Ltd executives and stock owners

Urovant Sciences Ltd executives and other stock owners filed with the SEC include:

• Cornelia Haag-Molkenteller,
  Chief Medical Officer of USI
• Bryan Smith,
  General Counsel - USI
• Michael McFadden,
  Chief Commercial Officer
• Christine Ocampo,
  Senior Vice President, Chief Accounting Officer, Principal Accounting Officer
• Kenton Stewart,
  Senior Vice President of Market Access
• Walt Johnston,
  Senior Vice President of Commercial
• James Hindman,
  Director
• Shigeyuki Nishinaka,
  Director
• Ajay Bansal,
  Chief Financial Officer, Senior Vice President - Business Development, Principal Financial Officer
• Myrtle Potter,
  Chairman of the Board
• James Robinson,
  Principal Executive Officer, Director
• Pierre Legault,
  Independent Director
• Sef Kurstjens,
  Independent Director
• Holdings Ltd.Dexcel Pharma ...,
  
• Associates Gp Llcqvt Fund V...,
  
• Patrick Machado,
  
• Frank Torti,
  Director
• Global Investors Lp Viking ...,
  
• Investments (Uk) Ltd Soft B...,
  
• Nori Ebersole,
  SVP&CHRO-Urovant Sciences,Inc.
• Global Performance Llc Viki...,
  
• Sciences Ltd. Roivant,
  10% owner
• Andrew Lo,
  
• Global Performance Llc Viki...,
  
• Associates Gp Llcqvt Financ...,
  
• Chemical Co., Ltd.Sumitomo ...,
  
• Keith Katkin,
  PEO;CEO/Urovant Sciences, Inc.